Starpharma
SYDNEY, May 23, 2011 -
Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announced
successful results of a major phase 2 clinical study that demonstrated
efficacy of VivaGel(R) for the treatment of bacterial vaginosis (BV).
